Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.

BACKGROUND AND AIMS Interferon-γ-inducible protein-10 [IP-10] mediates immune cell trafficking from the circulation to the inflamed colon and decreases gut epithelial cell survival. IP-10 expression is increased in patients with ulcerative colitis [UC]. We report efficacy and safety results from a dose-ranging induction study of eldelumab, a fully human monoclonal antibody to IP-10, in moderately to severely active UC. METHODS A total of 252 adults with UC [Mayo score ≥ 6 and endoscopic subscore ≥ 2] were randomised 1:1:1 to placebo or eldelumab 15 or 25 mg/kg administered intravenously on Days 1 and 8 and every other week thereafter. The primary endpoint was clinical remission [Mayo score ≤ 2; no individual subscale score > 1] at Week 11. Key secondary endpoints included Mayo score clinical response and mucosal healing at Week 11. RESULTS Neither eldelumab 15 or 25 mg/kg resulted in significant increases vs placebo in the proportion of patients achieving Week 11 clinical remission. Remission and response rates were 17.6% and 47.1% with eldelumab 25mg/kg, 13.1% and 44.0% with eldelumab 15mg/kg, and 9.6% and 31.3% with placebo. Clinical remission and response rates were higher in anti-tumour necrosis factor [TNF]-naïve patients treated with eldelumab compared with placebo. Eldelumab treatment was well tolerated and no immunogenicity was observed. CONCLUSIONS The primary endpoint was not achieved with induction treatment with eldelumab 15 or 25 mg/kg in patients with UC. Trends towards clinical remission and response were observed in the overall population and were more pronounced in anti-TNF naïve patients. Eldelumab safety signals were consistent with those reported previously [ClinicalTrials.gov number, NCT01294410].

[1]  A. Timmer,et al.  Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. , 2016, The Cochrane database of systematic reviews.

[2]  J. Mansfield,et al.  Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial , 2014, The Lancet.

[3]  M. Matsuura,et al.  Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience , 2014, BMC Gastroenterology.

[4]  S. Danese,et al.  New therapeutic avenues in ulcerative colitis: thinking out of the box , 2013, Gut.

[5]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[6]  W. Sandborn,et al.  Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study , 2013, Gut.

[7]  G. D'Haens,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[8]  S. Dudley-Brown,et al.  Ulcerative Colitis From Patients' Viewpoint: A Review of Two Internet Surveys , 2012, Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates.

[9]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[10]  M. Talamini,et al.  Ulcerative colitis , 2012, The Lancet.

[11]  P. Moayyedi,et al.  Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[12]  S. Schreiber,et al.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial , 2011, Gut.

[13]  M. Dubinsky,et al.  The Impact of Ulcerative Colitis on Patients’ Lives Compared to Other Chronic Diseases: A Patient Survey , 2010, Digestive Diseases and Sciences.

[14]  M. Dubinsky,et al.  Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey , 2009, Inflammatory bowel diseases.

[15]  K. Van Steen,et al.  Long-term outcome after infliximab for refractory ulcerative colitis. , 2008, Journal of Crohn's & colitis.

[16]  G. D'Haens,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial , 2008 .

[17]  E. Levitan,et al.  Meta-Analysis of the Placebo Response in Ulcerative Colitis , 2008, Digestive Diseases and Sciences.

[18]  Kenji Suzuki,et al.  Blockade of interferon‐γ‐inducible protein‐10 attenuates chronic experimental colitis by blocking cellular trafficking and protecting intestinal epithelial cells , 2007 .

[19]  C. Brensinger,et al.  A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. , 2007, Gastroenterology.

[20]  A. Timmer,et al.  Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. , 2007, The Cochrane database of systematic reviews.

[21]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[22]  A. Moss,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2006, Gastroenterology.

[23]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[24]  D. Peura Clinical implications of immediate-release PPI therapy in the management of GERD and upper GI bleeding. Introduction. , 2005, Alimentary pharmacology & therapeutics.

[25]  J. Weinstock,et al.  Anti‐Interferon‐inducible Chemokine, CXCL10, Reduces Colitis by Impairing T Helper‐1 Induction and Recruitment in Mice , 2005, Inflammatory bowel diseases.

[26]  B. Sands,et al.  Review article: practical management of inflammatory bowel disease patients taking immunomodulators , 2005, Alimentary pharmacology & therapeutics.

[27]  E. Loftus Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.

[28]  D. Taub,et al.  Inhibition of IFN-γ-Inducible Protein-10 Abrogates Colitis in IL-10−/− Mice 1 , 2003, The Journal of Immunology.

[29]  Kenji Suzuki,et al.  Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival , 2002, European journal of immunology.

[30]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.

[31]  M. Baggiolini,et al.  Short Communication Increased Expression of IP-10, IL-8, MCP-1, and MCP-3 in Ulcerative Colitis , 1999 .

[32]  G. Guyatt,et al.  A new measure of health status for clinical trials in inflammatory bowel disease. , 1989, Gastroenterology.

[33]  G. Guyatt,et al.  Quality of life in patients with inflammatory bowel disease. , 1988, Journal of clinical gastroenterology.

[34]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[35]  C. FordAlexander,et al.  ULCERATIVE colitis. , 1997, Journal of the American Medical Association.